Miami County Fair

Fun For All

How Oncotarget Became an Invaluable Resource Journal for Scientists

Who knew that barely a decade after launching, Oncotarget would rise to become a global online peer-to-peer reviewed publisher? The founding duo of Andrei V. Gudkov and Mikhail Blagosklonny had spent their entire careers researching in the biomedical realm. Over the years, the astute researchers had front row seats to the daunting challenges that effectively slowed down any meaningful scientific signs of progress. Something drastic and urgent had to be done.

Why Oncotarget?

Oncotarget was designed to be a platform to bring together scientists and researchers working on similar scientific problem sets. The outfit would drastically end the common redundancies that caused researchers to waste valuable time, resources and energies focusing on already solved medical issues. If successful, the platform would help eradicate the globe’s pressing medical conditions like cancers thanks to the heightened collaboration among the researchers at Oncotarget.

On 19th September 2017, Oncotarget released a presser to reaffirm their resolve to continue publishing two new multidisciplinary research findings every seven days. Updated content from the open access medical journal would be readily available at the following high-profile scientific achieves and research indexes: EMBASE, Scopus, PubMed, ISI/Web of Science Citation Index, BIOSIS Previews and on PubMed Central Index.

According to PR Newswire, Oncotarget is well on course to becoming the first-ever peer-to-peer reviewed publication index to have research findings published in PubMed within two days of posting the same content.

Oncotarget’s Partners

Collaborations with vested stakeholders have indeed played a pivotal role in Oncotarget’s rise to the top. The firm has partnered up with the public, medical researchers and practitioners to make sure speedy and accurate indexing of the research data received from their global audience. So far, the creative bio-medical journal has already submitted published seven bio-medical volumes and 324 issues to PubMed. The eighth volume was recently processed and approved by the National Library of Medicine.


Ideally, the scientific research, indexing firm intended to focus on oncology-related topics findings, alone. Over time, however, the surging demand for their essential services led them to diversify their scope and begin publishing on other medical niches, for instance, on Microbiology, Pathology, Autophagy, Immunology, and on Aging-related topics.